Reuters logo
BRIEF-Biomarin Pharma up 6.1 percent premarket; FDA panel backs approval of Morquio A Syndrome drug
November 20, 2013 / 12:50 PM / 4 years ago

BRIEF-Biomarin Pharma up 6.1 percent premarket; FDA panel backs approval of Morquio A Syndrome drug

NEW YORK, Nov 20 (Reuters) - BioMarin Pharmaceutical Inc : * Pharma up 6.1 percent premarket after FDA panel backs approval of Morquio A

Syndrome drug

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below